$3.87
0.51% yesterday
Nasdaq, Sep 27, 10:01 pm CET
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

MaxCyte Inc Stock price

$3.87
-0.37 8.73% 1M
-0.45 10.42% 6M
-0.83 17.66% YTD
+0.79 25.65% 1Y
-9.72 71.52% 3Y
+2.28 142.91% 5Y
+2.28 142.91% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.02 0.51%
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

Key metrics

Market capitalization $408.80m
Enterprise Value $270.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.94
P/S ratio (TTM) P/S ratio 9.00
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth 11.69%
Revenue (TTM) Revenue $45.44m
EBIT (operating result TTM) EBIT $-46.18m
Free Cash Flow (TTM) Free Cash Flow $-25.39m
Cash position $157.33m
EPS (TTM) EPS $-0.34
P/E forward negative
P/S forward 11.00
EV/Sales forward 7.27
Short interest 3.64%
Show more

Is MaxCyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

MaxCyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a MaxCyte Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a MaxCyte Inc forecast:

Buy
88%
Hold
13%

Financial data from MaxCyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
45 45
12% 12%
100%
- Direct Costs 9.45 9.45
8% 8%
21%
36 36
13% 13%
79%
- Selling and Administrative Expenses 53 53
16% 16%
117%
- Research and Development Expense 24 24
7% 7%
54%
-42 -42
13% 13%
-92%
- Depreciation and Amortization 4.38 4.38
20% 20%
10%
EBIT (Operating Income) EBIT -46 -46
14% 14%
-102%
Net Profit -35 -35
9% 9%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about MaxCyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MaxCyte Inc Stock News

Neutral
GlobeNewsWire
12 days ago
Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
Neutral
GlobeNewsWire
22 days ago
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-...
Neutral
Seeking Alpha
about 2 months ago
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2024 Earnings Call August 6, 2024 4:30 PM ET Company Participants Scott Feinberg - Investor Relations Maher Masoud - President and Chief Executive Officer Doug Swirsky - Chief Financial Officer Conference Call Participants Hannah Hefley - Stephens Julie Simmonds - Panmure Liberum Steven Mah - TD Cowen Matt Larew - William Blair Jack Siedow - Craig-Hallum Capital ...
More MaxCyte Inc News

Company Profile

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Maher Masoud
Employees 143
Founded 1998
Website www.maxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today